Compare XPL & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | TENX |
|---|---|---|
| Founded | 1984 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 71.1M |
| IPO Year | 2000 | 2001 |
| Metric | XPL | TENX |
|---|---|---|
| Price | $0.62 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.20 | ★ $29.67 |
| AVG Volume (30 Days) | 221.6K | ★ 4.7M |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.31 |
| 52 Week High | $0.98 | $19.40 |
| Indicator | XPL | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 27.98 |
| Support Level | $0.61 | $1.31 |
| Resistance Level | $0.80 | $2.22 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.00 | 0.41 |
| Stochastic Oscillator | 31.63 | 43.87 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.